GSK's Omjjara Secures Japanese Nod For Treatment of Myelofibrosis

GSK plc, a biotechnology company, reported that Japan's Ministry of Health, Labour and Welfare (MHLW) has endorsed Omjjara (momelotinib) for the treatment of myelofibrosis. Omjjara is an oral, once-daily inhibitor of JAK1/JAK2 and the activin A...

Roche Unveils New Analytical Units For Cobas pro Integrated Solutions

Roche, a leading biotechnology firm, declared the availability of its new analytical units, the cobas c 703 and cobas ISE neo, for the cobas pro integrated solutions, in nations accepting the CE mark. The cobas c 703 and cobas ISE neo logical...

ISTH Releases Clinical Practice Guideline For Haemophilia Treatment

The International Society on Thrombosis and Haemostasis (ISTH), the most prominent international professional medical-scientific organization committed to improving the understanding, prevention, diagnosis, and treatment of thrombotic and...

Melodia Therapeutics and Alivexis Ink Pact For Cathepsin C Inhibitor

Alivexis, Inc. furthermore, Melodia Therapeutics AG, an organization set up by Forty51 Endeavors, declared that they have forayed into an exclusive license agreement for the overall development, assembling, and commercialization of Alivexis...

Basilea Pharma and Glioblastoma Partner For Oncology Drug Candidate

Basilea Pharmaceutica Ltd., a commercial-stage biopharmaceutical firm with headquarters in Switzerland dedicated to treating patients with severe bacterial and fungal infections, declared that it has forayed into an asset purchase agreement...

Sanofi and Biovac Lead Polio Vaccine Manufacturing Capabilities

Sanofi and Biovac, a Cape Town, South Africa-based biopharmaceutical business, have announced a local manufacturing agreement to produce inactivated polio vaccines (IPV) in Africa. This partnership aims to enable regional manufacturing of polio...

© 2024 India Pharma Outlook. All Rights Reserved.